Western Blot: p19ARF/CDKN2A Antibody (12-A1-1) [NB200-169] - Analysis of endogenous p19Arf using NB200-169. Total cell lysates (25 ug) from NIH3T3 cells, which have deleted the Arf gene (Lanes 1) and from wild type ...read more
Immunocytochemistry/ Immunofluorescence: p19ARF/CDKN2A Antibody (12-A1-1) [NB200-169] - Immunofluorescent detection of p19Arf in wild type mouse embryo fibroblasts (MEF) at passage 5 (lanes 1, 2) and NIH3T3 cells, which ...read more
Immunoprecipitation: p19ARF/CDKN2A Antibody (12-A1-1) [NB200-169] - Total cell lysates (250 ug) from NIH3T3 cells which have deleted the Arf gene (Lanes 5) and from NIH3T3 cells expressing an HA-tagged version of p19Arf ...read more
By Western blot, this antibody recognizes bands at ~19 kDa.
Theoretical MW
19 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Publications
Read Publications using NB200-169 in the following applications:
ARF (alternative reading frame; p14ARF in human, p19ARF in mouse) is a tumor suppressor that serves as a sensor of hyper-proliferative signals, resulting in p53-dependent growth arrest and apoptotic cell death. ARF interacts with several proteins including COMMD1, CDKN2AIP, TBRG1, E4F1, C1QBP etc. and can bind to BCL6, E2F1, HUWE1, MDM2, MYC, NPM1/B23, TOP1/TOPOI as well as UBE2I/UBC9. ARF has the capability of inducing cell cycle arrest in G1 as well as G2 phases. While ARF is not expressed at significant levels in most normal tissues, oncogene activation triggers ARF overexpression, resulting in inhibition of MDM2 ubiquitin ligase and stabilization of p53. It is induced by progesterone as well as Ras/DMTF1, and is downregulated through NFkB p65 subunit (RELA). Inhibition of the p53 pathway, most commonly via mutations in p53 itself, inactivation of ARF, or amplification of MDM2 has been proposed to be a crucial step in pathogenesis of most human malignancies. Moreover, mice with null ARF have been shown to develop tumors rapidly and to display delayed mammary gland involution.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
=
÷
Review this Product
Be the first to review our p19ARF/CDKN2A Antibody (12-A1-1) and receive a gift card or discount.